



Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

This report highlights all changes (additions and deletions) to the CVS/caremark Performance Drug List.

ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
Brand Agents:			
Anoro Ellipta (umeclidinium/ vilanterol)	Respiratory/ Anticholinergic/Beta Agonist Combinations	Anoro Ellipta is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).	To provide the only long-acting anticholinergic and long-acting beta-2 agonist combination inhalation therapy for the treatment of COPD.
Bosulif (bosutinib)	Antineoplastic Agents/ Kinase Inhibitors	Bosulif is indicated for the treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) with resistance or intolerance to prior therapy.	To provide a tyrosine kinase inhibitor (TKI) therapy option for the second-line treatment of CML in a new Performance Drug List class.
Dexcom G4 (continuous blood glucose monitoring sensors, transmitters and receivers)	Endocrine and Metabolic/ Antidiabetics/Supplies	Not applicable.	To provide an additional diabetes testing option.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
Gleevec (imatinib mesylate)	Antineoplastic Agents/ Kinase Inhibitors	Gleevec is indicated for newly diagnosed patients with Ph+ CML in chronic phase (CP), Ph+ CML in blast crisis, accelerated phase or in CP after failure of interferon α therapy. Gleevec has multiple additional indications including use in Ph+ acute lymphocytic leukemia (Ph+ ALL) and is indicated in both adult and pediatric patients.	To provide a TKI therapy option with similar efficacy as other first-line agents for the treatment of CML in a new Performance Drug List class.
Sprycel (dasatinib)	Antineoplastic Agents/ Kinase Inhibitors	Sprycel is indicated for the treatment of: <ul style="list-style-type: none"> • Newly diagnosed adults with Ph+ CML in chronic phase. • Adults with chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Gleevec (imatinib). • Adults with Ph+ ALL with resistance or intolerance to prior therapy. 	To provide a TKI therapy option with similar efficacy as other first-line agents for the treatment of CML in a new Performance Drug List class.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
Generic Agents:			
ciprofloxacin suspension	Anti-infectives/ Antibacterials/ Fluoroquinolones	Ciprofloxacin suspension is indicated for the treatment of multiple infections caused by susceptible organisms in the conditions listed below. --Adult patients: <ul style="list-style-type: none"> • Urinary tract infections • Acute uncomplicated cystitis in females • Chronic bacterial prostatitis • Lower respiratory tract infections • Acute sinusitis • Skin and skin structure infections • Bone and joint infections • Complicated intra-abdominal infections (used in combination with metronidazole) • Infectious diarrhea • Typhoid fever (enteric fever) • Uncomplicated cervical and urethral gonorrhea --Pediatric patients (1 to 17 years of age): <ul style="list-style-type: none"> • Complicated urinary tract infections and pyelonephritis --Adult and pediatric patients:	The "A"-rated generic ciprofloxacin suspension will replace the branded agent Cipro Suspension (ciprofloxacin) on the Performance Drug List. The current listing, ciprofloxacin tablet, will be combined with ciprofloxacin suspension as a single listing, ciprofloxacin.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		<ul style="list-style-type: none"> Inhalational anthrax (post-exposure) 	
diclofenac sodium 1.5%	Analgesics/ NSAIDs, Topical	For the treatment of signs and symptoms of osteoarthritis of the knee(s).	The "A"-rated generic diclofenac sodium 1.5% (Pennsaid) will also be listed on the Performance Drug List
fenofibrate	Cardiovascular/ Antilipemics/Fibrates	<p>Fenofibrate is indicated as an adjunct to diet:</p> <ul style="list-style-type: none"> To reduce elevated low density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides (TG) and apolipoprotein B (Apo B), and to increase high density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. To reduce TG in adult patients with severe hypertriglyceridemia. 	The "A"-rated generic fenofibrate will replace the branded agent Lipofen (fenofibrate) on the Performance Drug List.
hydromorphone extended-release	Analgesics/ Opioid Analgesics	Hydromorphone extended-release is indicated in opioid-tolerant patients for the management of pain severe enough to require	The "A"-rated generic hydromorphone extended-release will replace the branded agent Exalgo (hydromorphone) extended-release on the Performance Drug List.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.	
morphine extended-release	Analgesics/ Opioid Analgesics	Morphine extended-release is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.	The "A"-rated generic morphine extended-release will replace the branded agent Avinza (morphine) extended-release on the Performance Drug List. Generic "morphine ext-rel" is already listed on the Performance Drug List.
moxifloxacin	Anti-infectives/ Antibacterials/ Fluoroquinolones	Moxifloxacin is indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible organisms in the conditions listed below: <ul style="list-style-type: none"> • Acute bacterial sinusitis • Acute bacterial exacerbation of chronic bronchitis • Community acquired pneumonia • Uncomplicated skin and skin structure infections • Complicated skin and skin structure infections • Complicated intra-abdominal 	The "A"-rated generic moxifloxacin will replace the branded agent Avelox (moxifloxacin) on the Performance Drug List.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.



Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		infections	
norelgestromin/ ethinyl estradiol transdermal	Endocrine and Metabolic/ Contraceptives/Transdermal	Norelgestromin/ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use a transdermal patch.	The "A"-rated generic norelgestromin/ethinyl estradiol transdermal will replace the branded agent Ortho Evra (norelgestromin/ethinyl estradiol) transdermal on the Performance Drug List.
raloxifene	Endocrine and Metabolic/ Selective Estrogen Receptor Modulators	Raloxifene is indicated for: <ul style="list-style-type: none">• Treatment and prevention of osteoporosis in postmenopausal women.• Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis.• Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.	The "A"-rated generic raloxifene will replace the branded agent Evista (raloxifene) on the Performance Drug List.
telmisartan/ hydrochloro- thiazide	Cardiovascular/ Angiotensin II Receptor Antagonists/Diuretic Combinations	Telmisartan/hydrochlorothiazide is indicated for the treatment of hypertension.	The "A"-rated generic telmisartan/hydrochlorothiazide will replace the branded agent Micardis HCT (telmisartan/hydrochlorothiazide) on the Performance Drug List.
tolterodine extended-release	Genitourinary/ Urinary Antispasmodics	Tolterodine extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary	To provide an additional generic therapy option.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		incontinence, urgency and frequency.	

DELETIONS:

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
Brand Agents:			
Avelox (moxifloxacin)	Anti-infectives/ Antibacterials/ Fluoroquinolones	Avelox is indicated for the treatment of bacterial infections caused by susceptible organisms in the conditions listed below: <ul style="list-style-type: none"> • Community acquired pneumonia • Acute exacerbations of chronic bronchitis • Acute bacterial sinusitis • Mild to Moderate pelvic inflammatory disease 	Avelox (moxifloxacin) will be replaced on the Performance Drug List by the "A"-rated generic, moxifloxacin.
Avinza (morphine extended-release)	Analgesics/ Opioid Analgesics	Avinza is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are	Avinza (morphine) extended-release will be replaced on the Performance Drug List by the "A"-rated generic morphine extended-release.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Performance Drug List Change Summary
Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		inadequate.	
<p>Cipro Suspension (ciprofloxacin)</p>	<p>Anti-infectives/ Antibacterials/ Fluoroquinolones</p>	<p>Cipro Suspension is indicated for the treatment of infections caused by susceptible organisms in the conditions listed below.</p> <p>--Adult patients:</p> <ul style="list-style-type: none"> • Urinary tract infections • Acute uncomplicated cystitis in females • Chronic bacterial prostatitis • Lower respiratory tract infections • Acute sinusitis • Skin and skin structure infections • Bone and joint infections • Complicated intra-abdominal infections (used in combination with metronidazole) • Infectious diarrhea • Typhoid fever (enteric fever) • Uncomplicated cervical and urethral gonorrhea <p>--Pediatric patients (1 to 17 years of age):</p> <ul style="list-style-type: none"> • Complicated urinary tract infections and pyelonephritis <p>--Adult and pediatric patients:</p> <ul style="list-style-type: none"> • Inhalational anthrax (post- 	<p>Cipro (ciprofloxacin) Suspension will be replaced on the Performance Drug List by the "A"-rated generic ciprofloxacin suspension.</p> <p>The current listing, ciprofloxacin tablet, will be combined with ciprofloxacin suspension as a single listing, ciprofloxacin.</p>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.



Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		exposure)	
Evista (raloxifene)	Endocrine and Metabolic/ Selective Estrogen Receptor Modulators	Evista is indicated for: <ul style="list-style-type: none"> • Treatment and prevention of osteoporosis in postmenopausal women. • Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. • Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. 	Evista (raloxifene) will be replaced on the Performance Drug List by the "A"-rated generic raloxifene.
Exalgo (hydromorphone extended-release)	Analgesics/ Opioid Analgesics	Exalgo is indicated in opioid-tolerant patients for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.	Exalgo (hydromorphone) extended-release will be replaced on the Performance Drug List by the "A"-rated generic hydromorphone extended-release.
Lipofen (fenofibrate)	Cardiovascular/ Antilipemics/Fibrates	Lipofen is indicated as an adjunct to diet: <ul style="list-style-type: none"> • To reduce elevated LDL-C, total-C, TG and Apo B, and to increase 	Lipofen (fenofibrate) will be replaced on the Performance Drug List by the "A"-rated generic fenofibrate.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.

Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia. • To reduce TG in adult patients with severe hypertriglyceridemia.	
Micardis HCT (telmisartan/ hydrochlorothiazide)	Cardiovascular/ Angiotensin II Receptor Antagonists/Diuretic Combinations	Micardis HCT is indicated for the treatment of hypertension.	Micardis HCT (telmisartan/hydrochlorothiazide) will be replaced on the Performance Drug List by the "A"-rated generic, telmisartan/hydrochlorothiazide.
Ortho Evra (norelgestromin/ ethinyl estradiol) transdermal	Endocrine and Metabolic/ Contraceptives/Transdermal	Ortho Evra is indicated for the prevention of pregnancy in women who elect to use a transdermal patch.	Ortho Evra (norelgestromin/ethinyl estradiol) transdermal will be replaced on the Performance Drug List by the "A"-rated generic norelgestromin/ethinyl estradiol transdermal.
Zuplenz (ondansetron) oral soluble film	Gastrointestinal/ Antiemetics	Zuplenz is indicated for: • Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. • Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. • Prevention of nausea and	Availability of other oral and transdermal therapy options indicated for prevention of nausea and vomiting, including other ondansetron products. Alternatives on the Performance Drug List include dronabinol, granisetron, meclizine, metoclopramide, ondansetron, prochlorperazine, promethazine, trimethobenzamide and Sancuso (granisetron) transdermal.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.



Performance Drug List Change Summary Report

Effective 10-01-2014

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Alternatives/Comments
		vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to abdomen or daily fractions to the abdomen. • Prevention of postoperative nausea and/or vomiting.	

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 Caremark Rx, L.L.C. All rights reserved.